Observation on the therapeutie effect of HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia in the elderly
1.Department of Hematology, Lihuili Hospital of Ningbo Medical Center, Ningbo, 315040; 2.Department of Hematology, the First Affiliated Hospital, Zhejiang University, Hangzhou, 310003
SONG Yanping1,LE Jing1,WAN Bin1, et al. Observation on the therapeutie effect of HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia in the elderly[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(6): 455-.
Objective: To analyse the treatment outcome of 20 newly diagnosed acute myeloid leukemia (AML) in the elderly patients, and explore the efficacy and safety of HAA regimen, which consisting of homoharringtonine (HHT), cytarabine (Ara-C) and aclarubicin (Acla). Methods: All of the patients enrolled were treated with HAA regimen. The complete remission (CR) rate was observed. Results: Out of the 20 patients, 14 (70%) attained CR and the first single course of this induction regimen resulted in a CR rate of 60%. The main side effects included myelosuppression, infections and gastrointestinal disorders. These side effects improved by support and anti-infection therapy and generally did not affect the treatment. Conclusion: HAA regimen is a safe regimen and it is efficacious, well-tolerable induction therapy for newly diagnosed AML in the elderly. A high CR rate can be achieved with only one or two courses of this regimen.
